All In Biotech

Drug Trial Radar · NCT06414330

Ringer Acetate Based Modified Del Nido Cardioplegia Solution Versus HTK Solution Cardioplegia Solution in Cardiac Surgery

Ringer Acetate Based Modified Del Nido Cardioplegia Solution Versus Histidine, Tryptophan and Ketoglutarate Solution Cardioplegia Solution in Cardiac Surgery

Last checked: Nov 20, 2026Latest source record: Dec 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 124 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

124

Actual

Start

Jun 1, 2024

Primary completion

Nov 12, 2025

Study completion Dec 1, 2025

Sponsor

Lead sponsor
Assiut UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Ahmed Ismail Abdelsabour; Ramy Mustafa Abdelgawad Mohamed; Ibrahim Mohamed Imbaby; Amr Ibrahim Abdelaal; Mahmoud Mohamed Atef Sallam; Mohamed, Ahmed Abdelhay Mohamed
First posted
May 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Low chloride solutions were proved to be better in resuscitation of emergency cases and decrease the resulting hyperchloremic metabolic acidosis in the last decade. In ringers' acetate solutions, there is acetate, which is metabolized in muscles to produce bicarbonate molecules, so neutralizing the ongoing lactic and hyperchloremic metabolic solutions. Both solutions were proved to be superior to normal saline as a fluid therapy plan in most studies with much less ongoing hyperchloremic metabolic acidosis and inflammatory response. In this protocol, modified Del Nido formula will be involved using ringers' acetate instead of plasmalyte solutions and comparing the effects on myocardial protection versus HTK solutions

Conditions

  • Cardiac Ischemia

Interventions

  • Ringer acetate based Del Nido cardioplegiaBiological

    All patients will receive hypothermia 29 - 32 ℃ and cardioplegia will be injected between the aortic valve and aortic cross clamp in a pressure not less than 50 mmHg above systolic pressure. After removal of aortic cross clamping, the heart will be monitored for ventricular arrhythmias, early recovery, and postoperative 24 hours serum troponin and new changes in echocardiography.

  • HTKBiological

    Giving HTK instead of Del Nido

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Any arrhythmia other than sinus rhythm after cross-clamp removal and reperfusionTime frame: after aortic declamping and reperfusion of the heart at the end of ischemia time during cardiopulmonary bypass

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Assiut university, faculty of medicine, anesthesia and ICU and pain management department

    Asyut, Asyut Governorate, Egypt

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.